NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside
Needham has initiated coverage on NewAmsterdam Pharma Company N.V (NASDAQ:NAMS), a clinical-stage biopharma developing obicetrapib, an orally-dosed CETP inhibitor for lowering cholesterol.
Needham已開始對NewAmsterdam Pharma Company N.V（納斯達克：NAMS）進行覆蓋，這是一家臨床階段的生物製藥公司，開發口服CETP抑制劑obicetrapib，用於降低膽固醇。
In July, NewAmsterdam Pharma released topline data from the Phase 3 BROOKLYN trial, the first of four studies in NewAmsterdam's pivotal clinical development program, to evaluate obicetrapib in adult patients with heterozygous familial hypercholesterolemia whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
7月，NewAmsterdam Pharma發佈了第3期BROOKLYN試驗的高端數據，這是NewAmsterdam關鍵臨床開發計劃中的四項研究之一，用於評估obicetrapib在接受最大可耐受的降脂治療但其LDL-C水平仍未得到充分控制的成年家族性高膽固醇血癥（heterozygous familial hypercholesterolemia）患者。
The study achieved the primary endpoint of LS mean reduction of in LDL-C on top of maximally tolerated lipid-modifying therapies at day 84 with a statistically significant reduction sustained at day 365.
該研究在84天內實現了LDL-C的LS平均減少，且在最大可耐受的脂質調節療法基礎上，該減少在365天內保持，並且有統計學顯著性減少。
Also Read: Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results.
還閱讀：儘管對研究結果反應褒貶不一，分析師對NewAmsterdam Pharma的膽固醇藥物表現持樂觀態度。
Obicetrapib lowered LDL-C by 36.3% on day 84 and 41.5% on day 365, compared to the placebo. The observed reductions in other biomarkers met statistical significance.
相比安慰劑，obicetrapib在第84天降低了36.3%的LDL-C，在第365天降低了41.5%。其他生物標誌物的觀察到的減少達到了統計學顯著性。
Needham highlights that Obicetrapib stands out from previous CETP inhibitors due to its lack of associated issues.
Needham指出，Obicetrapib與以往的CETP抑制劑不同之處在於其沒有相關問題。
The upcoming phase 3 trial results, expected in Q4 2024 and Q1 2025, could validate Obicetrapib's significant LDL-C reduction and favorable safety profile, potentially reducing the risk of major adverse cardiovascular events (MACE) by over 15% in the PREVAIL CVOT trial, with results anticipated in the second half of 2026.
預計2024年第四季度和2025年第一季度發佈的即將到來的第3期試驗結果可能證實Obicetrapib顯著降低LDL-C和有利的安全性特徵，有望在2026年下半年預期的PREVAIL CVOt試驗中將主要不良心血管事件（MACE）的風險降低15%以上。
The analyst initiates with a Buy rating and a price target of $36.
分析師開始給予買入評級，價格目標爲36美元。
If successful, Needham expects Obicetrapib to generate blockbuster sales of over $2 billion by targeting around 30 million patients.
如果成功，尼德漢姆預計Obicetrapib將通過針對約3000萬患者而帶來超過20億美元的暢銷業績。
In June 2024, NewAmsterdam announced a new US patent for Obicetrapib, protecting the drug until July 2043.
2024年6月，新阿姆斯特丹宣佈了一項新的美國專利，以保護Obicetrapib藥物直到2043年7月。
The company ended the second quarter with a cash position of $430.7 million.
公司第二季度以4,3070萬美元的現金地位結束。
Price Action: NAMS stock is up 0.12% at $16.69 at the last check Wednesday.
價格變動：NAMS股票上漲0.12%，報16.69美元，截至本週三最後一次查詢。
Read Next
閱讀下一篇
- Patterson CEO Blames Q1 Drag On Change Healthcare Cyberattack, 'Timing Of Corporate Expenses'
- 帕特森首席執行官將Q1的拖累歸咎於變革醫療網絡攻擊和企業費用的時機。
譯文內容由第三人軟體翻譯。